Author Topic: Rituxan (rituximab)  (Read 148 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
« Last Edit: February 02, 2020, 05:04:29 pm by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
From JAMA Neurology (January 7, 2019)--this is a link to the entire article, entitled "Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis":


https://jamanetwork.com/journals/jamaneurology/fullarticle/2719699?guestAccessKey=17fb9684-d054-4bd4-a067-c9e3bb1b9462&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaneurology&utm_content=olf&utm_term=010719

« Last Edit: January 07, 2019, 11:57:29 am by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
This small study found that patients treated with rituximab before switching to glatiramer acetate (Copaxone) were more likely to show NEDA (no evidence of disease activity) than patients who received placebo before the change to Copaxone. From PubMed, January 13, 2019:


https://www.ncbi.nlm.nih.gov/pubmed/30635477


Apparently the patients received 2 infusions of Rituxan before starting daily Copaxone injections (from ClinicalTrials.gov Identifier: NCT01569451).

Quote
Active Comparator: (Placebo and) Glatiramer Acetate
Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.


Experimental: Rituximab and Glatiramer Acetate (R-GA)
Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
« Last Edit: June 27, 2019, 03:52:10 pm by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Rituximab treatment for MS
« Reply #3 on: June 27, 2019, 03:50:11 pm »
More in support of rituximab for treatment of both RRMS and "progressive MS phenotypes," from PubMed (June 27, 2018):


https://www.ncbi.nlm.nih.gov/pubmed/31237800
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Multiple Sclerosis News Today (August 23, 2019)--"Aggressive MS in Child Dramatically Resolved with Rituximab Treatment, Case Study Reports":


http://bit.ly/2LdNgDM
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Rituximab in MS at general hospital level
« Reply #5 on: February 02, 2020, 05:00:56 pm »
From PubMed, February 2, 2020--abstract of a Swedish study, "Rituximab in multiple sclerosis at general hospital level":


https://www.ncbi.nlm.nih.gov/pubmed/31990978
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
From PubMed (February 20, 2020), "Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland":


https://www.ncbi.nlm.nih.gov/pubmed/32066031




MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
Rituximab biosimilar could be $4 billion blockbuster
« Reply #7 on: March 12, 2020, 04:32:49 pm »
ABP798, a rituximab biosimilar, is about to be marketed--and is expected to sell very well.


https://pharmaphorum.com/news/amgen-allergans-rituximab-biosimilar-could-be-4bn-blockbuster/
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
From Multiple Sclerosis Journal (March 17, 2020)--"Comparison of rituximab originator (MabThera) to biosimilar (Truxima) in patients with multiple sclerosis":


https://journals.sagepub.com/doi/abs/10.1177/1352458520912170
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest
Some of the authors of the article abstracted here are well known in MS research. From PubMed (August 10, 2020)--"Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment":


https://pubmed.ncbi.nlm.nih.gov/32767538/


Note that clicking on the DOI in the abstract will take you to the entire article.


There is also this--also indexed in PubMed (August 10) and with some of the same authors--"Serious safety events in rituximab-treated multiple sclerosis and related disorders":


https://pubmed.ncbi.nlm.nih.gov/32767538/
« Last Edit: August 10, 2020, 07:19:27 am by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8526
  • MS diagnosed 1980
  • Location: Pacific Northwest

More on this study, from Multiple Sclerosis News Today (August 11, 2020)--"Rituximab More Effective than Gilenya, Tecfidera and Comparable to Tysabri, Study Finds":


https://bit.ly/30ViwQX
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
80 Views
Last post March 14, 2016, 12:22:55 pm
by agate
1 Replies
122 Views
Last post June 14, 2017, 10:35:24 am
by agate
0 Replies
50 Views
Last post May 30, 2018, 12:19:55 pm
by agate
0 Replies
44 Views
Last post September 29, 2018, 11:36:07 am
by agate
0 Replies
35 Views
Last post October 05, 2019, 07:51:03 am
by agate